TY - JOUR
T1 - Chemokine receptors in advanced breast cancer
T2 - Differential expression in metastatic disease sites with diagnostic and therapeutic implications
AU - Cabioglu, N.
AU - Sahin, A. A.
AU - Morandi, P.
AU - Meric-Bernstam, F.
AU - Islam, R.
AU - Lin, H. Y.
AU - Bucana, C. D.
AU - Gonzalez-Angulo, A. M.
AU - Hortobagyi, G. N.
AU - Cristofanilli, M.
PY - 2009
Y1 - 2009
N2 - Background: We investigated the expression of CXCR4, CCR7, estrogen receptor (ER), progesterone receptor (PR) and HER2-neu in human metastatic breast cancers to determine whether these biological biomarkers were preferentially expressed in any organ-specific metastases. Materials and methods: CXCR4, CCR7, ER, PR and HER2-neu expression levels were evaluated by immunohistochemical staining using paraffin-embedded tissue sections of metastatic breast cancers (n = 41) obtained by either diagnostic biopsy or surgical resection. Results: The metastatic sites included the following: Bone (n = 15), brain (n = 14), lung (n = 6), liver (n = 2), and omental metastases (n = 2). CXCR4 was expressed in 41% of cases, CCR7 expression was demonstrated in 10%, and HER2-neu overexpression was present in 27%. CXCR4 was more likely to be expressed in bone metastases than visceral metastases (67% versus 26%, P = 0.020). Visceral sites demonstrated a lower rate of CXCR4 positivity (33% and 23%, respectively, for lung and brain metastases). Similarly, CCR7 was more likely to be found in bone metastases than visceral sites (27% versus 0%, P = 0.037). Conclusions: These results indicate that CXCR4 can contribute to the homing of breast cancer cells to the bone. This finding might have important clinical implications since patients with metastatic bone disease may achieve the highest benefit from a CXCR4-targeted therapy.
AB - Background: We investigated the expression of CXCR4, CCR7, estrogen receptor (ER), progesterone receptor (PR) and HER2-neu in human metastatic breast cancers to determine whether these biological biomarkers were preferentially expressed in any organ-specific metastases. Materials and methods: CXCR4, CCR7, ER, PR and HER2-neu expression levels were evaluated by immunohistochemical staining using paraffin-embedded tissue sections of metastatic breast cancers (n = 41) obtained by either diagnostic biopsy or surgical resection. Results: The metastatic sites included the following: Bone (n = 15), brain (n = 14), lung (n = 6), liver (n = 2), and omental metastases (n = 2). CXCR4 was expressed in 41% of cases, CCR7 expression was demonstrated in 10%, and HER2-neu overexpression was present in 27%. CXCR4 was more likely to be expressed in bone metastases than visceral metastases (67% versus 26%, P = 0.020). Visceral sites demonstrated a lower rate of CXCR4 positivity (33% and 23%, respectively, for lung and brain metastases). Similarly, CCR7 was more likely to be found in bone metastases than visceral sites (27% versus 0%, P = 0.037). Conclusions: These results indicate that CXCR4 can contribute to the homing of breast cancer cells to the bone. This finding might have important clinical implications since patients with metastatic bone disease may achieve the highest benefit from a CXCR4-targeted therapy.
KW - Bone metastases
KW - CCR7
KW - CXCR4
KW - HER2-neu
KW - Metastatic breast cancer
UR - http://www.scopus.com/inward/record.url?scp=66149145860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66149145860&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdn740
DO - 10.1093/annonc/mdn740
M3 - Article
C2 - 19237480
AN - SCOPUS:66149145860
SN - 0923-7534
VL - 20
SP - 1013
EP - 1019
JO - Annals of Oncology
JF - Annals of Oncology
IS - 6
ER -